Profile data is unavailable for this security.
About the company
Guizhou Sanli Pharmaceutical Co Ltd is a company mainly engaged in the research and development, production and sales of Chinese patent medicines. The Company's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The Company mainly sells its products through specialized academic marketing.
- Revenue in CNY (TTM)1.92bn
- Net income in CNY308.82m
- Incorporated1995
- Employees2.28k
- LocationGuizhou Sanli Pharmaceutical Co LtdXiayun Industrial Park, Pingba DistrictGUIYANG 550014ChinaCHN
- Phone+86 85 184607358
- Fax+86 85 138113572
- Websitehttps://www.gz-sanli.com/
More ▼
Mergers & acquisitions
| Acquired company | 603439:SHH since announced | Transaction value |
|---|---|---|
| Guizhou Hanfang Pharmaceutical Co Ltd | -27.04% | 68.45m |
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shouyao Holdings Co Ltd | 4.03m | -195.31m | 4.62bn | 185.00 | -- | 5.03 | -- | 1,146.82 | -1.31 | -1.31 | 0.0271 | 6.17 | 0.0036 | 0.2578 | 1.35 | 21,779.19 | -17.49 | -37.24 | -19.17 | -42.63 | 95.40 | 96.03 | -4,847.44 | -2,251.77 | 7.47 | -- | 0.0093 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Guizhou Sanli Pharmaceutical Co Ltd | 1.92bn | 308.82m | 4.89bn | 2.28k | 16.32 | 3.21 | -- | 2.54 | 0.7311 | 0.7311 | 4.59 | 3.72 | 0.7844 | 2.50 | 4.26 | 843,357.60 | 12.76 | 12.39 | 19.35 | 16.72 | 70.14 | 70.45 | 16.27 | 16.31 | 1.52 | -- | 0.2486 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Shanghai Haoyuan Chemexpress Co Ltd | 2.05bn | 103.00m | 5.02bn | 3.37k | 48.58 | 1.92 | -- | 2.44 | 0.4911 | 0.4911 | 9.79 | 12.45 | 0.4922 | 1.03 | 3.90 | 609,696.60 | 2.43 | 7.38 | 3.29 | 9.60 | 42.71 | 47.03 | 4.93 | 13.53 | 0.9905 | 3.08 | 0.3088 | 14.37 | 38.44 | 44.33 | -34.18 | 47.24 | 48.95 | -- |
| Wuhan Keqian Biology Co Ltd | 932.75m | 309.38m | 5.28bn | 923.00 | 16.96 | 1.40 | -- | 5.66 | 0.6681 | 0.6681 | 2.01 | 8.07 | 0.2072 | 2.09 | 2.79 | 1,010,559.00 | 6.86 | 13.29 | 8.07 | 15.49 | 66.77 | 76.49 | 33.11 | 45.71 | 3.93 | -- | 0.0637 | 24.76 | 6.27 | 7.67 | -3.32 | 0.3556 | 27.17 | -- |
Data as of Sep 13 2024. Currency figures normalised to Guizhou Sanli Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 11.10m | 2.72% |
| HFT Investment Management Co., Ltd.as of 30 Sep 2023 | 3.57m | 0.88% |
| Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 3.35m | 0.82% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.31m | 0.57% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 2.01m | 0.49% |
| Hotland Innovation Asset Management Co. Ltd.as of 31 Dec 2023 | 1.98m | 0.49% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.11m | 0.27% |
| JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 2023 | 922.70k | 0.23% |
| Baoying Fund Management Co., Ltd.as of 31 Dec 2023 | 861.50k | 0.21% |
| China Europe Fund Management Co., Ltd.as of 31 Dec 2023 | 848.60k | 0.21% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
